Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
Univ Copenhagen, Rigshosp, Copenhagen Prostate Canc Ctr, Copenhagen, Denmark..
Gothenburg Univ, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden..
Ferring Pharmaceut, Copenhagen, Denmark..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences. Lakarhuset & Uppsala Univ, Lakarhuset Urol, St Persgatan 17,5, SE-75320 Uppsala, Sweden..
Show others and affiliations
2016 (English)In: THERAPEUTIC ADVANCES IN UROLOGY, ISSN 1756-2872, Vol. 8, no 2, p. 75-82Article in journal (Refereed) Published
Abstract [en]

Objectives: The objective of this study was to assess differences in efficacy outcomes between luteinizing hormone-releasing hormone (LHRH) agonist plus antiandrogen (AA) flare protection and monotherapy with the gonadotrophin-releasing hormone antagonist degarelix in patients with prostate cancer. Methods: Data from 1455 patients were pooled from two prospective, phase III randomized 1-year clinical trials of degarelix versus LHRH agonist with or without AA. The AA bicalutamide was administered at the investigator's discretion. Adjusted hazard ratios (HRs) were calculated using a Cox proportional hazards regression model and a conditional logistic regression model was used for a case-control analysis of odds ratios (ORs). Results: Patients received degarelix monotherapy (n = 972) or LHRH agonist (n = 483) of whom 57 also received AA. Overall, prostate-specific antigen progression-free survival (PSA PFS) was improved with degarelix versus LHRH agonist + AA (Cox proportional hazards regression model-adjusted HR for PSA PFS failure was 0.56 [95% confidence interval (CI) 0.33-0.97, p = 0.038]). To compensate for a higher proportion of patients with metastases, Gleason score 7-10, and PSA >20 ng/ml in the LHRH agonist + AA group, a case-control analysis using a conditional logistic regression model was utilized. This resulted in an OR for PSA PFS of 0.42 (95% CI 0.20-0.89; p = 0.023) in the overall population, and 0.35 (95% CI 0.13-0.96; p = 0.042) in patients with PSA >50 ng/ml at baseline, when treated with degarelix versus LHRH agonists + AA. There were a small number of deaths, 1.9% with degarelix and 7% with LHRH agonists + AA (case-control analysis OR = 0.37; p = 0.085). Conclusions: Degarelix monotherapy produced a more favorable effect on PSA PFS outcomes than a LHRH agonist + AA flare protection therapy in patients with prostate cancer when a case-control analysis was used to compensate for differences between treatment groups.

Place, publisher, year, edition, pages
2016. Vol. 8, no 2, p. 75-82
Keyword [en]
anti-androgen, degarelix, luteinizing hormone-releasing hormone agonist, prostate cancer, testosterone flare
National Category
Urology and Nephrology
Identifiers
URN: urn:nbn:se:uu:diva-317715DOI: 10.1177/1756287215621471ISI: 000393741200001PubMedID: 27034720OAI: oai:DiVA.org:uu-317715DiVA, id: diva2:1082577
Available from: 2017-03-17 Created: 2017-03-17 Last updated: 2017-03-17Bibliographically approved

Open Access in DiVA

fulltext(599 kB)38 downloads
File information
File name FULLTEXT01.pdfFile size 599 kBChecksum SHA-512
5c703fe80f9cd0e26b359c84cd79813a593d7da7feb66b8770ce6521b735adc616aa81cd1e20554d284e197415c98b509e0134b38f240d91f783bfe5c2354e05
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed
By organisation
Department of Medical Sciences
Urology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar
Total: 38 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 459 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf